Cargando…
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. It is overexpressed/amplified in approximately 20% of gastric or gastroesophageal junction cancers. HER2 is being developed as a therapeutic target in a va...
Autor principal: | Ariga, Shin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219249/ https://www.ncbi.nlm.nih.gov/pubmed/37240498 http://dx.doi.org/10.3390/jcm12103391 |
Ejemplares similares
-
HER2-targeted advanced metastatic gastric/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives
por: Li, Weiling, et al.
Publicado: (2022) -
Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022) -
Challenges and future of HER2-positive gastric cancer therapy
por: Ma, Chenzhe, et al.
Publicado: (2023) -
Current and future landscape of targeted therapy in HER2-positive
advanced breast cancer: redrawing the lines
por: Simmons, Christine, et al.
Publicado: (2022) -
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)